Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

Rhea-AI Summary

Vor Bio (Nasdaq: VOR) and collaborator RemeGen announced that China’s NMPA has conditionally approved telitacicept for adult IgA nephropathy, the first BAFF/APRIL-targeting therapy for IgAN and the drug’s fourth approved indication.

Approval is based on Phase 2 and Phase 3 TELIGAN data showing a 59% UPCR reduction and favorable safety.

Positive

• NMPA grants conditional approval of telitacicept for adult IgA nephropathy in China
• First BAFF/APRIL-targeting therapy approved for IgA nephropathy (IgAN)
• Telitacicept now has four approved indications, expanding its clinical footprint
• Phase 3 TELIGAN met primary endpoint with 59% UPCR reduction at Week 39
• Placebo-adjusted UPCR reduction of 55% demonstrates strong comparative effect
• TELIGAN data show favorable safety profile and preserved kidney function
• Vor Bio holds exclusive rights to develop and commercialize telitacicept outside Greater China

Negative

• None.

News Market Reaction – VOR

+0.99%

4 alerts

+0.99% Session close to close

-7.7% Trough Tracked

$747.22M Market Cap

0.1x Rel. Volume

In the Jun 8 session, VOR gained 0.99%, reflecting a mild positive market reaction. Argus tracked a trough of -7.7% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights NMPA conditional approval of telitacicept for IgA nephropathy, backed b...

Analysis

This announcement highlights NMPA conditional approval of telitacicept for IgA nephropathy, backed by Phase 2 and Phase 3 data showing a 59% UPCR reduction and preserved eGFR over 39 weeks. It adds a fourth approved indication and reinforces the BAFF/APRIL inhibition strategy for autoimmune disease. In context, Vor Bio has been advancing late-stage telitacicept programs while maintaining substantial cash resources, and investors may watch future regulatory milestones and commercialization progress outside Greater China.

Key Figures

UPCR reduction (active): 59% reduction Placebo-adjusted UPCR effect: 55% reduction Telitacicept dose: 240 mg +4 more

7 metrics

UPCR reduction (active) 59% reduction Change from baseline at Week 39 with telitacicept 240 mg

Placebo-adjusted UPCR effect 55% reduction Placebo-adjusted reduction in UPCR at Week 39 in TELIGAN

Telitacicept dose 240 mg Dose used in Phase 3 TELIGAN primary analysis

Treatment duration 39 weeks Period over which UPCR and eGFR were assessed in TELIGAN

Indications approved 4 indications IgA nephropathy marked the fourth indication approval for telitacicept

Phase 2 trial ID 18C014 Completed Phase 2 IgAN trial supporting NMPA approval

Phase 3 trial ID 18C021 Part A TELIGAN Phase 3 IgAN trial supporting NMPA approval

Historical Context

5 past events · Latest: Jun 01 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 01	Inducement equity grants	Neutral	-6.3%	Equity awards to new hires under 2023 Inducement Plan with option and RSU grants.
May 28	Conference participation	Neutral	-3.3%	Announcement of corporate update at Jefferies Global Healthcare Conference with webcast.
May 14	Clinical data update	Positive	-5.3%	Interim Phase 3 TELIGAN NEJM publication showing strong UPCR reduction and stable eGFR.
May 13	Earnings and update	Neutral	-3.4%	Q1 2026 financials and update on global Phase 3 telitacicept trials and cash runway.
May 04	Inducement equity grants	Neutral	+5.5%	Inducement stock options and RSUs granted to new employees under 2023 plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news, including positive clinical and corporate updates, often coincided with downside moves in the shares.

Recent Company History

Over the last few months, Vor Bio has reported several corporate and clinical milestones, yet most were followed by negative price reactions. An interim Phase 3 TELIGAN analysis in IgA nephropathy on May 14, 2026 showed strong proteinuria reduction but the stock fell about 5.3%. Routine items like inducement grants and a conference appearance in early June also saw modest declines. Q1 2026 earnings highlighted a substantial cash balance and strategic pivot to autoimmune trials, again followed by weakness. Today’s conditional approval in China extends this pattern of fundamental progress against a soft trading backdrop.

Key Terms

baff/april-targeting, iga nephropathy, igan, phase 3, +3 more

7 terms

baff/april-targeting medical

"First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN)"

Therapies that target BAFF and APRIL block two immune‑system proteins (BAFF and APRIL) that help certain white blood cells survive and make antibodies. For investors, these drugs matter because they can change the course of autoimmune and antibody‑driven diseases, so clinical trial results, safety signals or regulatory decisions about BAFF/APRIL‑targeting treatments can significantly affect a biotech’s commercial prospects and valuation — like turning down signals that keep an overactive immune system running.

iga nephropathy medical

"First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN)"

A kidney disease caused when deposits of the antibody called IgA collect in the tiny filters of the kidney, gradually reducing their ability to clear waste — like grit building up in a water filter. It matters to investors because it creates demand for diagnostics, drugs and long‑term care, drives clinical trial activity and regulatory decisions, and can influence the financial outlook of companies in pharma, biotech, medical devices and health insurance.

igan medical

"First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN)"

IgAN, short for IgA nephropathy, is a chronic kidney disease in which an immune protein called IgA builds up in the kidneys, slowly damaging the filters that remove waste from the blood. Think of it as rust accumulating in a water filter: over time the filter clogs and performance declines. It matters to investors because it is a leading cause of kidney failure with large unmet treatment needs, driving clinical development, regulatory milestones, and potential market opportunity for new therapies.

phase 3 medical

"The NMPA approval was supported by positive results from the Phase 3 TELIGAN trial"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

randomized, double-blind, placebo-controlled medical

"a multicenter, randomized, double-blind, placebo-controlled study evaluating telitacicept"

A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.

urinary protein-to-creatinine ratio medical

"The primary endpoint was change from baseline in urinary protein-to-creatinine ratio (UPCR)"

A urinary protein-to-creatinine ratio is a lab measure that compares the amount of protein in a urine sample to the amount of creatinine, a stable waste product, to estimate how much protein the kidneys are leaking without requiring a full day's collection. Think of it as measuring how much dye has leaked into water relative to a standard marker to account for dilution. Investors care because elevated or changing values signal kidney damage or improvement, which can affect drug safety, trial results, diagnostic demand, and company valuations.

cd19+ b cells medical

"Additional findings included reductions in circulating CD19+ B cells and serum immunoglobulin"

CD19+ B cells are a group of immune cells (B lymphocytes) identified by a specific protein, CD19, on their surface—think of CD19 as a name tag that lets doctors and researchers find and count these cells. They matter to investors because changes in their number or function are used as markers of how well B-cell‑targeting drugs, vaccines or immune therapies are working and can signal safety or efficacy issues that affect a company’s clinical and commercial prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) 

Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published in The New England Journal of Medicine

IgAN marks the fourth indication approval for telitacicept

BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, and RemeGen Co., Ltd., (HKEX: 9995, SHA: 688331) today announced that China’s National Medicinal Products Administration (NMPA) has conditionally approved telitacicept for the treatment of adult patients with IgAN.

The conditional approval is supported by positive efficacy and safety data from RemeGen's completed Phase 2 trial (18C014) and Phase 3 TELIGAN trial (18C021 Part A) in IgAN. RemeGen independently developed telitacicept and is responsible for its development, regulatory approvals, and commercialization in China. Vor Bio holds exclusive rights to develop and commercialize telitacicept outside of Greater China.

“We are delighted to see telitacicept receive NMPA conditional approval in IgA nephropathy, representing an important achievement for the field and the first regulatory approval of a BAFF/APRIL-targeting therapy for IgAN,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of Vor Bio. “We congratulate our collaborator RemeGen on the successful development, regulatory submission, and approval of telitacicept in China. Together with the positive Phase 3 TELIGAN results recently published in The New England Journal of Medicine, this milestone further validates the potential of dual BAFF/APRIL inhibition to address the underlying immunopathology of IgAN and supports our belief that telitacicept has the potential to become a foundational therapy across multiple autoimmune diseases globally.”

The NMPA approval was supported by positive results from the Phase 3 TELIGAN trial, a multicenter, randomized, double-blind, placebo-controlled study evaluating telitacicept in adults with IgAN. The primary endpoint was change from baseline in urinary protein-to-creatinine ratio (UPCR) at Week 39.

In the primary analysis, patients treated with telitacicept 240 mg achieved a 59% reduction in UPCR from baseline at Week 39, corresponding to a 55% placebo-adjusted reduction. The study met its primary efficacy endpoint and demonstrated a favorable safety profile.

As previously reported in The New England Journal of Medicine, telitacicept treatment was also associated with encouraging preservation of kidney function. Estimated glomerular filtration rate (eGFR) remained largely stable through 39 weeks of treatment, while greater declines were observed in the placebo arm. Additional findings included reductions in circulating CD19+ B cells and serum immunoglobulin levels, including IgA, consistent with telitacicept's mechanism of action.

About Telitacicept
Telitacicept is a novel recombinant fusion protein designed to treat autoimmune diseases through dual inhibition of BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology.

Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG).

Vor Bio is advancing telitacicept in global Phase 3 trials in gMG and SjD to support potential regulatory approvals in the United States, Europe, and Japan.

About IgA Nephropathy
IgA nephropathy (IgAN) is one of the most common primary glomerular diseases worldwide and a leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD). It is characterized by IgA-containing immune complex deposition in the kidney, leading to inflammation, proteinuria, hypertension, and progressive loss of renal function. Up to 40% of patients progress to ESRD within 20 years of diagnosis, underscoring the significant unmet need for effective therapies. Current treatment approaches, including optimized blood pressure control, renin-angiotensin system blockade, and SGLT2 inhibitors, primarily slow disease progression but do not address the underlying immunopathology.

The prevailing scientific consensus is that overproduction of galactose-deficient IgA1 (Gd-IgA1) is a central driver of IgAN. BAFF and APRIL, two cytokines critical to B-cell survival and function, promote the production of Gd-IgA1 and its pathogenic antibodies.

About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “can,” “continue,” “could,” “design,” “enable,” “expect,” “initiate,” “intend,” “may,” “on-track,” “ongoing,” “plan,” “potential,” “should,” “target,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding the potential of dual BAFF/APRIL inhibition to address the underlying immunopathology of IgAN; telitacicept’s potential to become a foundational therapy across multiple autoimmune diseases globally potential for telitacicept to become a best-in-class dual BAFF/APRIL therapy across autoimmune diseases and to deliver meaningful benefit for patients globally; Vor Bio’s development and commercialization plans for telitacicept; and other statements that are not historical fact.

Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including the data for our product candidates may not be sufficient for obtaining regulatory approval to commercialize products; we may not be able to execute our business plans, including meeting our planned clinical and regulatory milestones and timelines, and possible limitations of financial and other resources. The results of the clinical trial described in this press release are based on information reported by RemeGen; Vor Bio has not independently verified this data. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission.

Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

FAQ

What did Vor Bio (VOR) announce about telitacicept approval in China on June 8, 2026?

Vor Bio announced that China’s NMPA granted conditional approval for telitacicept to treat adult IgA nephropathy. According to Vor Bio, the decision is based on completed Phase 2 and Phase 3 TELIGAN data showing efficacy, safety, and significant reductions in urinary protein-to-creatinine ratio.

Why is telitacicept’s NMPA conditional approval for IgA nephropathy important for Vor Bio (VOR)?

The conditional approval validates telitacicept’s clinical profile and supports its potential in autoimmune diseases. According to Vor Bio, this fourth indication and first BAFF/APRIL-targeting approval in IgAN also strengthen the rationale for its exclusive development and commercialization rights outside Greater China.

What were the key Phase 3 TELIGAN trial results supporting telitacicept approval for IgA nephropathy?

The Phase 3 TELIGAN trial met its primary endpoint of UPCR change at Week 39. According to Vor Bio, telitacicept 240 mg achieved a 59% UPCR reduction from baseline and a 55% placebo-adjusted reduction, with a favorable safety profile and largely preserved kidney function versus placebo.

How does telitacicept work as a BAFF/APRIL-targeting therapy for IgA nephropathy (VOR)?

Telitacicept targets BAFF and APRIL, cytokines involved in B-cell activity and immunoglobulin production. According to Vor Bio, treatment in TELIGAN reduced circulating CD19+ B cells and serum immunoglobulin levels, including IgA, consistent with its mechanism and potential to address underlying IgAN immunopathology.

What is the primary endpoint used in the TELIGAN Phase 3 trial for telitacicept in IgA nephropathy?

The primary endpoint was change from baseline in urinary protein-to-creatinine ratio (UPCR) at Week 39. According to Vor Bio, telitacicept 240 mg achieved a 59% UPCR reduction, corresponding to a 55% placebo-adjusted reduction, supporting NMPA conditional approval for adult IgAN in China.

Does Vor Bio (VOR) have global rights to telitacicept following the NMPA approval for IgA nephropathy?

Vor Bio does not control telitacicept in China but holds ex-China rights. According to Vor Bio, RemeGen leads development, regulatory approvals, and commercialization in China, while Vor Bio has exclusive rights to develop and commercialize telitacicept outside Greater China.